0
Editorials |

A Step Forward in COPD ManagementA Step Forward in COPD Management: Reading Between the Lines

Kenneth R. Chapman, MD, FCCP
Author and Funding Information

From the University of Toronto, and Asthma & Airway Centre, University Health Network, Toronto Western Hospital.

Correspondence to: Kenneth R. Chapman, MD, FCCP, Asthma & Airway Centre, University Health Network, Toronto Western Hospital, Room 7-451 E Wing, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada; e-mail: kchapman@ca.inter.net


Financial/nonfinancial disclosures: The author has reported to CHEST the following conflicts of interest: Dr Chapman has received compensation for consulting with Boehringer Ingelheim GmbH; CSL Behring; GlaxoSmithKline; Merck Frosst; Novartis AG; Takeda Pharmaceuticals International GmbH; Pfizer, Inc; Hoffman-La Roche, Inc; Merck & Co; and Grifols SA; has undertaken research funded by AstraZeneca; Boehringer Ingelheim GmbH; CSL Behring; Forest Laboratories, Inc; GlaxoSmithKline; Novartis AG; ParanGenix, Inc; Hoffman-La Roche, Inc; Takeda Pharmaceuticals International GmbH; and Grifols SA; and has participated in continuing medical education activities sponsored in whole or in part by AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline; Grifols SA; Merck Frosst; Novartis AG; Takeda Pharmaceuticals International GmbH; and Pfizer, Inc. Dr Chapman holds the GSK-CIHR Research Chair in Respiratory Health Care Delivery at the University Health Network.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2012;142(5):1082-1085. doi:10.1378/chest.12-0981
Text Size: A A A
Published online

Extract

The survival of patients with COPD is improving, albeit slowly, as a result of a series of modest enhancements in our management. In this issue of CHEST (see page 1104), Rodrigo and Neffen1 remind us of the latest of these incremental steps—the introduction of indacaterol, the first of the once-daily long-acting β2 agonists (LABAs) for the treatment of COPD.

Rodrigo and Neffen1 have reviewed the properties of indacaterol, contrasting it with currently available agents. Their thoughtful review suggests that indacaterol is not only an effective once-daily bronchodilator, but also may be more effective in clinical terms than once-daily tiotropium or bid LABAs such as formoterol and salmeterol. What is the likely impact of indacaterol’s availability in our management of COPD? Some might regard a once-daily LABA as a convenience to patients who might achieve a similar outcome with a bid LABA taken regularly. However, the data analyzed by Rodrigo and Neffen1 suggest that the sustained bronchodilator effect of indacaterol produces not only greater spirometric benefit than bid LABAs such as formoterol, but also differences accompanied by better patient-reported outcomes such as dyspnea and health status scores. Moreover, we suspect that compliance with a once-daily agent will be better than compliance with a bid agent, an issue better assessed in the real world than in the double-blind environment of phase 3 drug development.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543